---
title: "RBC Capital Sticks to Its Sell Rating for Sionna Therapeutics, Inc. (SION)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286343585.md"
description: "RBC Capital's Brian Abrahams has maintained a Sell rating on Sionna Therapeutics, Inc. (SION) with a price target of $23.00, while the stock closed at $40.94. Despite this, the overall analyst consensus for Sionna is a Strong Buy, with an average price target of $52.86. Abrahams has a 10.1% average return and a 51.10% success rate on his stock recommendations."
datetime: "2026-05-14T01:47:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286343585.md)
  - [en](https://longbridge.com/en/news/286343585.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286343585.md)
---

# RBC Capital Sticks to Its Sell Rating for Sionna Therapeutics, Inc. (SION)

In a report released on May 12, Brian Abrahams from RBC Capital maintained a Sell rating on Sionna Therapeutics, Inc., with a price target of $23.00. The company’s shares closed yesterday at $40.94.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, BioCryst, and ACADIA Pharmaceuticals. According to TipRanks, Abrahams has an average return of 10.1% and a 51.10% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sionna Therapeutics, Inc. with a $52.86 average price target.

### Related Stocks

- [SION.US](https://longbridge.com/en/quote/SION.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [BCRX.US](https://longbridge.com/en/quote/BCRX.US.md)
- [ACAD.US](https://longbridge.com/en/quote/ACAD.US.md)

## Related News & Research

- [LifeSci Capital Reaffirms Their Buy Rating on Sionna Therapeutics, Inc. (SION)](https://longbridge.com/en/news/286649459.md)
- [Sionna Therapeutics Q1 net loss widens, misses estimates](https://longbridge.com/en/news/286086578.md)
- [RBC Capital Sticks to Its Hold Rating for Lakefront Biotherapeutics (LKFT)](https://longbridge.com/en/news/286254871.md)
- [RBC Capital Sticks to Its Hold Rating for aTyr Pharma (ATYR)](https://longbridge.com/en/news/286843768.md)
- [RBC Capital Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)](https://longbridge.com/en/news/286342985.md)